MDS Day conference for MDS physicians, scientists and clinical nurse specialists – 21/11/2011
MDS patients – please inform your local clinical staff of this event.
NICE – National Institute for Health and Clinical Excellence – finally recommend azacitidine is available through the NHS for intermediate 2 and high-risk MDS, AML and CMML for England and Wales. The MDS UK Patient Support Group, which has been in consultation with NICE during the approval process and campaigned on behalf and in conjunction with MDS patients across the UK for almost 2 years, welcomes this announcement.
Full details in the news page.Read full story
NICE, the National Institute for Health and Clinical Excellence is running a survey about their work amongst the general public – and health professionals. Please do take part – even if you are not familiar with all aspects of their activities.Read full story
The Independent supplement on Blood disorders – published on the 2nd September (not the 30th Aug as initially planned).Read full story
Join the newly formed Cambridge Regional Group – contact us for details – and get a chance to meet-up every 3-4 months. Read more.Read full story
The MDS UK Patient Support Group today expressed its anger and disappointment at the announcement by the Scottish Medicines Consortium that is not recommending Vidaza (azacitidine) be made available through NHS Scotland to patients with a range of life-threatening bone marrow diseases.Read full story
'Cancer experts from more than 30 hospitals across Europe have joined a campaign to get an expensive life-extending drug on the NHS', writes Daily Telegraph's medical correspondent Kate Devlin.Read full story